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a b s t r a c t
Duchenne/Becker muscular dystrophy (DMD/BMD) is a recessive, X-linked disorder caused
by a mutation in the dystrophin gene. Deletions account for approximately 60–65% of
mutations, duplications for 5–10%. The remaining cases are mainly point mutations.
According to Monaco theory clinical form of the disease depends on maintaining or dis-
rupting the reading frame. The purpose of the study was to determine frequency and
location of deletions and duplications in the dystrophin gene, to determine the compliance
between maintaining/disrupting the reading frame and clinical form of the disease and to
check the effectiveness of MLPA (multiplex ligation-dependent probe ampliﬁcation) in the
detection of these mutations in hemizygous patients and heterozygous female carriers. The
material is composed of combined results of molecular diagnosis carried out in years 2009–
2012 in 180 unrelated patients referred with the diagnosis of DMD/BMD tested by use of
MLPA. We identiﬁed 110 deletions, 22 duplication (in one patient two different duplications
were detected) and 2 point mutations. Deletions involved mainly exons 45–54 and 3–21,
whereas most duplications involved exons 3–18. The compliance with Monaco theory was
95% for deletions and 76% for duplications. Most of mutations in the dystrophin gene were
localized in the hot spots – different for deletions and duplications. MLPA enabled their quick
identiﬁcation, exact localization and determination whether or not they maintained or
disrupted the reading frame. MLPA was also effective in detection of deletions and duplica-
tions in female carriers.
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Duchenne/Becker muscular dystrophies (DMD/BMD) are ge-
netic X-linked recessive disorders. DMD and BMD are the most
common dystrophinopathies, with an incidence of 1:3500 and
1:1800 live birth males, respectively [1,2]. Both diseases lead to
progressive irreversible muscle deterioration [3,4]. DMD shows
an earlier onset and a more severe progression [5].
DMD and BMD are caused by mutations in the dystrophin
gene (2.4 Mb), localized on the chromosome Xp21.2 [6,7],
comprises 79 exons encoding a 14 kb mRNA transcript [6]. The
protein product, dystrophin, has a molecular weight of
427 kDa, connects extracellular matrix with cytoskeleton [8].
Dystrophin is missing in DMD patients (<3%), whereas BMD
patients have 10–40% of the normal protein or produce
dystrophin of abnormal molecular weight [9].
Approximately 65% DMD cases and up to 85% of BMD cases
are caused by large deletions in DMD gene [6,10,11]. Duplica-
tions account for approximately 5–10% of the mutations
[12–15], whereas the remaining 25–30% are point mutations
and microlesions [16].
According to Monaco's theory, frameshifting mutations
generally cause more DMD, while in BMD the reading frame is
usually intact. This frameshifting model complies with
phenotype in 92%. This rule, however, is more in keeping
with deletions than with duplications in whom the reading of
ORF is less predictable and that may be due to the fact that
some duplications are inverted [17–20].
Most deletions cluster within two hot spot regions, the major
site encompassing exons 44–52 (70%) and a minor site including
exons 3–19 (30%). Duplications concentrate in proximal part of
the dystrophin gene. Point mutations do not cluster in certain
regions therefore they are more difﬁcult to detect [16]. Since no
effective therapy is available for DMD/BMD patients so far, the
identiﬁcation of female carriers is essential for genetic
counseling and prenatal diagnosis. Although approximately
98% of deletions can be found in patients by using a multiplex
polymerase chain reaction (PCR), this technique is not useful in
detecting female carriers since deletions in one dystrophin
allele are masked by the presence of the normal chromosome X.
Multiple ligation-dependent probe ampliﬁcation (MLPA) is a
new reliable method for detection deletions and duplications
both in male patients and female carriers [21–23]. MLPA
technique may also be a very useful tool for mutation detection
in female carriers from DMD/BMD families, where DNA sample
from a patient is not available.
2. The aim of the studies
1. Detection of deletions and duplications in 180 unrelated
DMD/BMD patients by MLPA method.
2. Determination of size and frequency of the deletions and
duplications found in the dystrophin gene of 180 DMD/BMD
families.
3. Detection of deletions and duplications in 62 females,
mothers of a single affected male, including 4 women from
DMD families, in which DNA samples from probands were
not available.4. Veriﬁcation of Monaco's theory for detected deletions and
duplications.
3. Materials
A total of 180 DMD/BMD families entered this study. A group of
134 patients was diagnosed with DMD (Duchenne muscular
dystrophy), 37 with BMD (Becker muscular dystrophy), 8 with
DMD/BMD (presymptomatic period in very young patients)
and 1 with IMD (intermediate form). In 4 DMD cases DNA from
a patient was not available and DNA from the mothers was
used for mutation analysis. Diagnosis was based on clinical
presentation, family history, markedly elevated serum kinase
levels and electromyography and progression of the disease,
results immunohistochemistry in most of the cases was not
available. In addition to these cases 62 mothers of a single
affected male were added to this study, including 4 mothers of
patients who deceased before molecular analysis was carried
out. All the examined families originated from Poland. All the
participants gave written informed consent to this study. The
institute performing the study is a referral center receiving
most samples from throughout the whole country.
4. Methods
DNA samples were obtained from peripheral blood lympho-
cytes according to standard procedures (MagNA Pure Compact,
Roche). Mutations in the DMD gene were detected by multiple
ligation-dependent probe ampliﬁcation (MLPA) technique
according to instructions of the manufacturer (MRC-Holland,
Amsterdam, The Netherlands). Two sets of reagents for
analysis of all 79 exons of the dystrophin gene were used:
SALSA probe mix 034 (exons 1–10, 21–30, 41–50 and 61–70) and
SALSA probe mix 035 (exons 11–20, 31–40, 51–60 and 71–79).
Ampliﬁed products were run on ABI PRISM 3100 Genetic
Analyzer. The obtained data were visually analyzed for the
detection of deletions and duplications. Two or more peaks
missing, corresponding to two or more exons, were represent-
ing a deletion. Absence of only one peak was additionally
investigated by standard PCR method. If PCR did not conﬁrm a
deletion, ampliﬁed product of analyzed exon was subsequent-
ly sequenced according to Sanger [24].
5. Results
MLPA analysis showed the presence of 134 mutations in 133
DMD genes in 180 DMD/BMD patients (73.9%). Deletions have
been detected in 110 patients (61.1%) (Table 1), duplications – in
21 (11.7%) (Table 2), point mutations in – 2 (1.1%) (c.134delA in
exon 3, c.5407C>T in exon 38). Two independent duplications
have been found in one family [25]. No mutations were
identiﬁed in 47 probands (26.1%). There were 75 DMD (75/134,
56.0%), 29 BMD (29/37, 78.4%), 5 DMD/BMD (5/8, 62.5%) and
1 IMD (1/1) patients with deletions and 17 DMD (17/134, 12.7%),
3 BMD (3/37, 8.1%), 1 DMD/BMD probands with duplications.
Two DMD patients had point mutations.
Table 1 – Deletions in DMD gene detected by use of MLPA in the group of 180 unrelated patients with the clinical suspicion
of DMD/BMD. Most frequent deletions were: exons 48–50 T 7 (6.4%), exons 45 T 5 (4.5%), exons 45–47 T 5 (4.5%) and exons
45–50 T 5 (4.5%).
Family Mutation Reading
frame
Phenotype Family Mutation Reading
frame
Phenotype
1298 I/C Del 1–18 In DMD 1474 I/NC Del 45–50 Out DMD
1345 I/C Del 2–16 Out DMD 1515 I/C Del 45–50 Out DMDa
1364 Del 3–7 Out DMD 1306 I/C Del 45–52 Out DMD
1343 Del 3–9 In BMD 1386 Del 45–52 Out DMDa
1354 I/C Del 3–9 In BMD 1411 Del 45–52 Out DMD
1392 I/NC Del 3–11 Out IMD 1497 Del 45–52 Out DMD
1430 I/NC Del 3–12 In D/BMD 1413 I/C Del 45–53 In BMD
1396 Del 3–20 In BMD 1483 Del 45–53 In BMD
1503 Del 3–30 In DMD 1408 Del 45–54 Out DMD
1390 I/C Del 4–7 Out DMDa 1473 Del 45–54 Out DMD
1333 I/C Del 4–16 In DMD 1332 Del 45–55 In BMD
1400 I/NC Del 5–7 Out DMD 1353 Del 45–55 In BMD
1461 I/C Del 5–7 Out BMD 1344 Del 46–47 Out DMD
1490 Del 5–7 Out DMD 1429 I/NC Del 46–47 Out DMD
1465 Del 5–9 In BMD 1457 I/NC Del 46–47 Out DMD
1404 I/C Del 6 Out DMD 1301 Del 46–48 Out DMD
1393 Del 7–34 Out DMD 1253 Del 46–50 Out DMD
1297 Del 8–9 Out DMD 1453 Del 46–51 Out DMD
1438 I/NC Del 8–10 Out DMD 1398 I/C Del 46–52 Out DMD
1395 I/C Del 8–13 Out DMD 1489 I/NC Del 46–52 Out DMD
1403 I/C Del 9–20 In BMD 1439 I/NC Del 46–55 Out DMD
1480 Del 10–21 Out DMD 1347 Del 47–50 Out DMD
1315 Del 12–13 Out DMD 1314 I/C Del 48 In BMD
1447 Del 12–25 Out DMD 1428 I/C Del 48 In BMD
1326 Del 12–43 In BMD 1523 Del 48 In BMD
1266 Del 13–41 In BMD 1366 Del 48–49 In BMD
1471 I/C Del 16–43 Out DMD 1401 Del 48–49 In BMD
1278 Del 17–43 Out DMD 1317 I/NC Del 48–50 Out DMD
1436 I/C Del 18–21 Out DMD 1319 I/C Del 48–50 Out DMD
1324 I/C Del 19–48 In D/BMD 1328 I/NC Del 48–50 Out DMD
1318 I/NC Del 20 Out DMD 1346 Del 48–50 Out DMD
1339 I/NC Del 41–43 Out DMD 1464 I/NC Del 48–50 Out DMD
1342 Del 44 Out DMD 1466 Del 48–50 Out DMD
1418 Del 44 Out DMD 1491 Del 48–50 Out DMD
1426 I/NC Del 44 Out DMD 1275 Del 48–51 In BMD
1376 Del 44–47 Out D/BMD 1510 Del 48–51 In BMD
1352 Del 44–55 Out DMD 1450 I/C Del 48–52 Out DMD
1302 I/NC Del 45 Out DMD 1475 Del 48–52 Out DMD
1355 Del 45 Out DMD 1280 I/C Del 48–54 Out DMD
1368 Del 45 Out DMD 1460 I/NC Del 48–56 Out DMD
1373 I/C Del 45 Out DMD 1300 Del 49–50 Out DMD
1525 I/NC Del 45 Out DMD 1369 Del 49–50 Out DMD
1287 Del 45–47 In BMD 1380 Del 49–50 Out DMD
1321 I/NC Del 45–47 In BMD 1476 Del 49–52 Out DMD
1350 Del 45–47 In D/BMD 1495 I/NC Del 49–54 Out DMD
1399 I/C Del 45–47 In D/BMD 1335 Del 50 Out BMD
1493 I/C Del 45–47 In BMD 1263 Del 50–51 In BMD
1270 I/NC Del 45–48 In BMD 1414 I/NC Del 51–55 Out DMD
1336 Del 45–48 In BMD 1256 I/NC Del 52 Out DMD
1446 I/C Del 45–48 In BMD 1292 Del 52 Out DMD
1281 Del 45–49 In BMD 1513 I/C Del 52 Out DMD
1459 I/NC Del 45–49 In BMD 1265 Del 52–54 Out DMD
1377 I/NC Del 45–50 Out DMD 1517 Del 53–54 Out DMD
1379 I/NC Del 45–50 Out DMD 1274 Del 56–79 Out DMD
1449 I/C Del 45–50 Out DMD 1309 I/C Del 65–79 Out DMD
D/BMD – young patient, without possibility of observation and classiﬁcation of clinical symptoms. I/C – isolated case of DMD/BMD, mother is a
carrier. I/NC – isolated case of DMD/BMD, mother is not a carrier.
a Cases of mutations detected in women from the families with DMD examined in situation of lack of proband's DNA.
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Table 2 – Duplications in DMD gene detected by use of
MLPA in the group of 180 unrelated patients with the




1279 Dup 2 Out DMD
1299 I/C Dup 2–7b In DMDa
1420 Dup 3 In BMD
1506 Dup 3–5 In DMD
1311 Dup 4–7 Out DMD
1507 Dup 5–18 In BMD
1422 I/C Dup 7–15 Out DMD
1273 I/NC Dup 8–11 Out DMD
1434 I/C Dup 8–17 Out DMD
1486 Dup 8–44 Out DMD
1295 Dup 11–44 In BMD
1378 Dup 12–13 Out DMD
1329 Dup 28–43 Out DMD
1250 I/C Dup 44 Out DMD
1500 Dup 45–51 In DMD
1524 I/C Dup 50 Out DMD
1299 Dup 50–59b In DMDa
1271 Dup 50–60 In DMD
1522 I/C Dup 51–72 Out DMD
1249 Dup 53 Out D/BMD
1257 Dup 63 Out DMD
1501 I/NC Dup 64–67 Out DMD
D/BMD – young patient, without possibility of observation and
classiﬁcation of clinical symptoms. I/C – isolated case of DMD/
BMD, mother is a carrier. I/NC – isolated case of DMD/BMD, mother
is not a carrier.
a Cases of mutations detected in women from the families with
DMD examined in situation of lack of proband's DNA.
b Two independent duplications detected in one allele.
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79.1% (87/110) of all the deletions identiﬁed in the study, of
which 3-exons deletions were the most frequent (19/110,
17.3%), followed by single-exon (17/110, 15.5%) and two-exon
deletions (12/110, 10.9%).
Exons 45–54 (74/110, 67%) and 3–21 (31/110, 28%) were the
most commonly deleted. Single-exon deletions occurred
mainly in exons 44, 45, 48 and 52 (14/17). Exon 48 was the
most frequently deleted (51/110, 46%), followed by exon 49
(45/110, 41%).
Small duplications involving less than 10 exons accounted
for 63% (14/22) of all the duplications detected in this study, of
which single-exon duplications were the most frequent (6/22,
27%). Exons 8–15 (7/22, 31%) were most frequently duplicated.
Exons 11–13 were most commonly duplicated (6/22, 27%).
Frame-shift deletions were identiﬁed in 96% of DMD
deletions (72/75). In frame deletions resulted in 93% of BMD
patients (27/29). Out of frame duplications were detected in 72%
of DMD duplications (13/18); all three BMD duplications were in
frame. Monaco's theory has been proved in 95% of deletions (99/
104) and in 76% of duplications (16/21) in our study.
MLPA analysis showed presence of a mutation in 34 of
62 mothers from DMD/BMD families with a single affected
male (56%). Deletion was identiﬁed in 28 females (28/54 52%)
and duplication – in 6 (6/8 75%) (Tables 1 and 2). In 4 of
these carriers mutations were identiﬁed in absence of DNA
from probands (3 deletions, 1 tandem duplication). Casesrepresenting ‘‘de novo’’ mutation, deletion or duplication,
account for 44% (28/62).
6. Discussion
Multiple ligation-dependent probe ampliﬁcation (MLPA) is a
very reliable method for detection deletions and duplications in
DMD/BMD patients [21–23,26]. Deletions have been identiﬁed in
61% of patients, duplications – in 12%, point mutations in two
cases (1%), which resulted in sensitivity of mutation detection
by MLPA of 74%. Our data conﬁrm an observation that deletions
are more frequently found in BMD patients (78%) than DMD
patients (56%). MLPA analysis showed presence of a deletion or
duplication in 86% of BMD patients and in 69% DMD patients. A
search for point mutations in the remaining patients (26%) is
going to be carried following immunohistochemistry of the
muscle samples to conﬁrm clinical diagnosis. Point mutations
occurring in sequences hybridizing to the MLPA probes may be
detected as false-negative results [21,27]. Two point mutations
identiﬁed in this study, were ﬁrst identiﬁed as MLPA single exon
deletions. Both exons, were successfully ampliﬁed by standard
PCR and sequenced, showing presence of point mutations:
c.134delA in exon 3 (p.Q45Rfs*7) and c.5407C>T in exon 38 (p.
Q1803*).
Location of deletions and duplications, detected in this
study, stayed in agreement with data published by other
authors [21–23,26–28]. Deletions clustered within two hot spots,
mayor encompassing exons 44–52 (68%) and minor site
including exons 3–19 (28%). The highest concentration of
duplications was found in proximal part of the gene, between
exons 8 and 15 (27%) (Fig. 1). Distribution of breakpoints (Fig. 2) is
in accordance with the published data for the West-European
population [29].
Like in our previous report [28], small deletions, including
less than 10 exons, were found to be predominant in this study
(84%). We also conﬁrm an observation made by other
researchers that majority of duplications are small ones,
encompassing less than 10 exons (73%) [10,13–15].
Off all the exons, exon 48 was the most frequently deleted,
followed by exon 49, and exons 50; exons 11–13 were most
commonly duplicated.
According to Monaco's theory, clinical severity of the disease
results from either disruption or preservation of the reading
frame by a mutation. Frameshifting mutations usually cause
DMD, while in BMD the reading frame stays intact. Monaco's
theory complies with phenotype in 90% [13–15]. In our study 96%
of deletions in DMD and 93% of deletions in BMD were consisted
with the reading frame rule. In our study, two cases of BMD
resulted from out of frame deletions (exons 5–7 and 50),
inconsistently with Monaco's rule. Most likely additional exons
were removed by alternative splicing, restoring reading frame:
exon 8 in the ﬁrst and exon 51 in the second case. Out of frame
deletion of exons 5–7 was also detected in two DMD patients.
Different phenotypes resulting from the same mutation were
also reported by other researches [30]. Accuracy of the model for
duplications is lower and should be applied carefully [14]. Out of
frame duplications were found in 72% of DMD patients. This is in
accordance with the results of other authors [14,19,30]. Less













Fig. 1 – Relative frequency of deletions and duplications in exons of dystrophin gene for 110 deletions and 22 duplications
detected by use of MLPA in the group of 180 unrelated patients with the clinical suspicion of DMD/BMD.
n e u r o l o g i a i n e u r o c h i r u r g i a p o l s k a 4 8 ( 2 0 1 4 ) 4 1 6 – 4 2 2420duplications may be explained by their effects on splicing RNA
and the resulting synthesis of dystrophin. The inverted
duplications were reported [20] to cause disruption the
transcription [26].Fig. 2 – Distribution of intronic breakpoints of deletions (A) and 
starting breakpoints (50 breakpoint, black) and ending breakpoin
duplications respectively localized in each intron are indicated.Identiﬁcation of female carriers is essential for DMD/BMD
families, since there is no effective treatment for the disease.
In the families with a single affected male, it is fundamental to
determine whether the disease resulted from a 'de novo'duplications (B) within the dystrophin gene. The number of
ts (30 breakpoint, grey bars) of either deletions and
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MLPA technique is a very useful tool for mutation detection in
female carriers, in which deletions and duplications are not
detectable in by standard PCR method [21–23,27]. In our study
56% of the mothers of single affected males were found to be
carriers of mutations, in remaining 44% carriership was ruled
out proving the occurrence of 'de novo' mutations. Similar
results were published for the populations of North India [31],
Mexico [32] and Australia [33]. French results, however, were
different; de novo mutations were reported only in 24.5% of the
isolated cases [13]. The differences may be due to statistical
biases e.g. – probability of familial cases being recorded is
higher than in isolated cases; it is also possible that some
noncarrier females – mothers of DMD/BMD isolated cases in
our material are in fact germinal mosaics.
MLPA is also a powerful tool for carriership analysis in DMD
families, in which DNA sample from patient is not available. In
our study four of the mothers were found to be carriers of
mutations detected in absence of DNA sample from a patient
(three deletions, one case of two independent duplications).
MLPA technique seems to be a reliable tool in the screening of
deletions and duplications in the dystrophin gene both in DMD/
BMD patients and potential female carriers, especially those,
who cannot be investigated by other methods. The mutation
data resulted from this study may be used for and experimental
gene therapy of DMD patients, involving ‘‘exon skipping’’
approach [34] and further genotype/phenotype studies. The
results of carriership status analysis are an essential tool for
genetic counseling and prenatal diagnosis in DMD/BMD fami-
lies.
7. Conclusions
1. Localization of ‘‘hot spots’’ in the dystrophin gene is
different for deletions and duplications.
2. Precise determination of size and location of a deletion in the
dystrophin gene allows for prediction of clinical form of the
dystrophy; in case of duplication, this correlation is lower.
3. MLPA technique is a quick, convenient and efﬁcient tool for
deletion and duplication detection both in affected patients
and female carriers, therefore carriership testing of DMD/
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